Should I Buy ANAB? ANAB 2026 Analysis

Should You Buy AnaptysBio Inc (ANAB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

45.090

1 Day change

-5.77%

52 Week Range

52.470

Analysis Updated At

2026/01/28

ANAB is not a good buy right now for a beginner long-term investor who is impatient. The trend is still broadly bullish (moving averages stacked up), but price is already pressing near resistance, momentum is cooling (MACD histogram slightly negative), options positioning is heavily bearish (puts dominate), and insider selling has surged. Without an Intellectia buy signal today, the risk/reward for entering immediately is not attractive—better to hold off rather than buy at this level.

Technical Analysis

Pre-market: ~$49.98 (+0.50%). Trend: bullish structure with SMA_5 > SMA_20 > SMA_200, indicating an uptrend is intact. Momentum: MACD histogram -0.0126 (below 0) and negatively contracting—suggests upside momentum is weakening/pausing rather than accelerating. RSI(6)=68.19 (upper-neutral, close to overbought), consistent with a stretched near-term move. Levels: Pivot 47.416. Resistance R1 49.804 (price is essentially at/just above this level pre-market), next R2 51.279. Support S1 45.029 then S2 43.554. Near-term pattern stats provided imply modest drift: ~-0.83% next day, +0.74% next week, +2.4% next month—more consistent with consolidation than a clean breakout from here. Intellectia Proprietary Trading Signals: **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bearish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Options snapshot (2025-11-19): Put open interest 17,438 vs call open interest 2,503 (very put-heavy; OI put/call 6.97). Volume put/call 2.97 (puts also leading on the day). IV: 30D IV 87.23 vs HV 66.18 (implied > realized), but IV rank/percentile are low (IV rank 12.54; IV percentile 22.8), suggesting current IV is not elevated versus its own recent history. Interpretation: positioning/sentiment leans defensive/bearish (heavy puts), which conflicts with the bullish moving-average trend and argues against chasing the current price near resistance.

Technical Summary

Sell

Buy

Positive Catalysts

Analyst-cited catalyst strength: increased conviction in ANB033 (Barclays raised PT to $78 on 2026-01-20). Prior positive Phase I read-through for ANB033 supported major valuation uplift (Guggenheim PT $140 on 2025-12-18). Broader biotech sentiment improving into 2026 per UBS upgrade to Buy with PT $70 (2026-01-07).

Neutral/Negative Catalysts

Sentiment/flow negatives: insiders are selling and the selling amount increased 189.75% over the last month. Options market is strongly put-skewed (OI put/call 6.97; volume put/call 2.97), implying meaningful downside hedging/speculation. Fundamental/program overhang: rosnilimab Phase 2 ulcerative colitis miss and discontinuation in UC previously drove multiple target cuts (2025-11-10 to 2025-11-11). No supportive news flow in the last week to act as a fresh upside trigger.

Financial Performance

Latest quarter: 2025/Q3. Revenue rose to $76.32M (+154.26% YoY), showing strong top-line growth/recognition. However, profitability deteriorated versus the prior year: net income $15.11M (-146.00% YoY) and EPS $0.52 (-145.61% YoY). Gross margin reported at 100% (flat), suggesting revenue mix/recognition supports high gross margin, but below-the-line items are pressuring net results. Overall: strong revenue growth, weaker earnings trend.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings remain broadly constructive (Buy/Overweight/Outperform), and price targets have rebounded sharply after late-2025 cuts. Sequence: multiple PT reductions in Nov–Dec 2025 after the UC setback (e.g., Wedbush to $50, Wainwright to $52, Barclays to $70 then $55, Stifel to $56). Then sentiment improved with ANB033 enthusiasm and broader biotech tailwinds: Guggenheim raised PT to $140 (2025-12-18), UBS upgraded to Buy with PT $70 (2026-01-07), and Barclays lifted PT to $78 (2026-01-20). Wall Street pros: pipeline/catalyst upside (ANB033), improving biotech tape, and potential royalty value (per Guggenheim). Cons: prior clinical disappointment in UC remains a credibility/derisking concern, and the market’s options positioning plus insider selling suggest investors are still cautious despite higher targets. Politicians/congress: no recent congress trading data available; no influential-figure trading data provided.

12 Analyst Rating

Wall Street analysts forecast ANAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANAB is 71.33 USD with a low forecast of 50 USD and a high forecast of 140 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

1 Hold

0 Sell

Strong Buy

Current: 47.850

Low

Averages

71.33

High

140

Current: 47.850

Low

Averages

71.33

High

140

Barclays

Etzer Darout

Overweight

maintain

$55 -> $78

AI Analysis

2026-01-20

Reason

Barclays

Etzer Darout

Price Target

$55 -> $78

AI Analysis

2026-01-20

maintain

Overweight

Reason

Barclays analyst Etzer Darout raised the firm's price target on AnaptysBio to $78 from $55 and keeps an Overweight rating on the shares. The firm cites increased conviction in ANB033 for the target boost.

UBS

Neutral -> Buy

upgrade

$20 -> $70

2026-01-07

Reason

UBS

Price Target

$20 -> $70

2026-01-07

upgrade

Neutral -> Buy

Reason

UBS upgraded AnaptysBio (ANAB) to Buy from Neutral with a price target of $70, up from $20, as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANAB

Unlock Now

ANAB Should I Buy

ANAB Should I Buy

Should You Buy AnaptysBio Inc (ANAB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch